Cost-utilityGenotypingOvarian-cancer, diagnosisThe article reports on the findings by researchers from the University of Rochester School of Medicine that BRCA 1/2 genetic testing of women at high risk of carrying the BRCS 1 or 2 gene mutations, and treatment of those who test positive, seems ...
“If all women with triple-negative breast cancers who are younger than 50 in the USA were to be tested systematically forBRCAmutations, our model predicts as much as a 23% reduction in new breast cancers and a 41% reduction in ovarian cancers, at acceptable cost. We believe that this cri...
The standard cost of a BRCA test in the UK is currently d530 (NHS, 2014). There are several different NGS platforms available at present, all of which have slight variations in requirements and output. Each platform has variable costs per sample and costs for the sequencing equipment, but ...
BRCAtesting in women with breast cancer is cost-effective and is associated with reduced risk of cancer and improved survival. Extending testing to cover family members of affected women who test positive improves cost-effectiveness beyond restricting testing to affected women only. Introduction A germ...
The appropriate management of breast cancer risk in BRCA mutation carriers following ovarian cancer diagnosis remains unclear. We sought to determine the s... Charlotte,Gamble,J Laura,... - 《Annals of Surgical Oncology》 被引量: 3发表: 2017年 A Multigene Test Could Cost-Effectively Help Extend...
given the varied ethnic composition of the populations. To develop a test that might be useful throughout the region and therefore sufficiently cost-effective, it is first necessary to determine whichBRCA1/2mutations are common in multiple countries. Public insurance coverage for genetic testing is ...
The nomogram showed an AUC of 0.824 in the validation set for predicting the gBRCA mutation status of patients with BC. It may be used as pre-screening tool to improve the cost-effectiveness of genetic testing before it is performed, thus contributing to precision medicine. Although the ...
Using both in silico tools and an in vitro kinase activity test, the majority of the variants were found likely to be deleterious for protein function. One variant present in both cases and controls was proposed to be neutral. Removing this variant from the pool of potentially deleterious ...
Who (and what) to test forBRCAmutation The value of gBRCA1/2m testing for cancer risk reduction in breast and ovarian cancer is well-established.17,18,19To date, researchers from the Breast Cancer Information Core (https://research.nhgri.nih.gov/bic/) have collated more than 1800 mutations...
Who (and what) to test forBRCAmutation The value of gBRCA1/2m testing for cancer risk reduction in breast and ovarian cancer is well-established.17,18,19To date, researchers from the Breast Cancer Information Core (https://research.nhgri.nih.gov/bic/) have collated more than 1800 mutations...